BEAM NASDAQ
Beam Therapeutics Inc.
1W: +0.9%
1M: -16.4%
3M: -30.6%
YTD: -9.7%
1Y: +1.5%
3Y: +1.0%
5Y: -74.1%
$24.50
+0.11 (+0.45%)
Weekly Expected Move ±7.9%
$21
$23
$24
$26
$28
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
1 bullish
2 neutral
1 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (100)
Most and least shorted mid- to mega-cap healthcare stocks at the end of September
Elon Musk led Tesla, SpaceX take center stage in Cathie Wood’s Ark portfolio
Beam alleges Chinese biotech, and its U.S. partner Serapha stole trade secrets
Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike
AM Markets Need to Know: F-35 parts end up in Chinese custody, Google nears Gemini 4 launch, and more
Engineers Gate Manager LP Reduces Stock Holdings in Beam Therapeutics Inc. $BEAM
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10 mid-cap U.S. healthcare stocks with the weakest momentum grades
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
Cathie Wood's Ark weekly recap: buys Meta, gene-editing stocks while cutting Alphabet
Traders Buy Large Volume of Beam Therapeutics Call Options (NASDAQ:BEAM)
Beam drops after updating Phase 1/2 trial data for gene-editing drug
3 Promising Genomics Stocks in the Spotlight in 2026
At a glance: stocks gapping up premarket
Most shorted stocks on Wall Street
Most and least shorted mid- to mega-cap healthcare stocks at the end of August
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down – Should You Sell?
Biotech Breakout: What's in focus after Moderna's cancer win?
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of “Moderate Buy” by Brokerages
Amova Asset Management Americas Inc. Has $91.16 Million Stock Holdings in Beam Therapeutics Inc. $BEAM
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Tesla, AMD, and SpaceX headline Cathie Wood's biggest H1 portfolio bets
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Abu Dhabi expo puts Beam's off-grid EV chargers before UAE buyers - Stock Titan
Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure
Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now? - Yahoo Finance
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?
A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress - simplywall.st
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation”
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation” - Yahoo Finance
Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake - Stock Titan
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
12 Stocks to Buy After Meta’s Deal to Beam Energy From Space - InvestorPlace
3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat
Why Beam Therapeutics Stock Is Sliding Again - TipRanks
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
BEAM Forecast, Price Target & Analyst Ratings | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit Facility - Has The Bull Case Changed?
Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit Facility - Has The Bull Case Changed? - Yahoo Finance
Three Best Genomics Stocks for Your Portfolio in 2026
Beam Therapeutics Stock Rockets After Breakthrough Data - TipRanks
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. - The Motley Fool
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares
Beam Therapeutics (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 11,810 Shares
Beam Therapeutics (NASDAQ:BEAM) CEO John Evans Sells 30,078 Shares
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Why is BEAM stock edging higher after hours today? - MSN
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM
John Evans Sells 25,000 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock
Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years - Yahoo Finance
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Beam Therapeutics CEO Evans sells $1.1m in stock - Investing.com
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names
How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding
How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Shares Up 5.5% After Analyst Upgrade
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
Beam Therapeutics shares climb after positive BEAM-302 trial update - MSN
Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics stock jumps on positive trial data - Investing.com
Beam Therapeutics Inc. $BEAM Position Increased by Hudson Bay Capital Management LP
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - Yahoo Finance